A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 when Administered to Participants with Alzheimer's Disease and Vascular Pathology

Grants and Contracts Details

StatusFinished
Effective start/end date2/16/2211/30/23

Funding

  • PPD Investigator Services LLC: $48,739.00